These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 22908061)

  • 21. Expression of somatostatin receptor 2A in medullary thyroid carcinoma is associated with lymph node metastasis.
    Herac M; Niederle B; Raderer M; Krebs M; Kaserer K; Koperek O
    APMIS; 2016 Oct; 124(10):839-45. PubMed ID: 27539746
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evidence for Somatostatin receptor 2 in thyroid tissue.
    Druckenthaner M; Schwarzer C; Ensinger C; Gabriel M; Prommegger R; Riccabona G; Decristoforo C
    Regul Pept; 2007 Jan; 138(1):32-9. PubMed ID: 16996150
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Peptide receptor radionuclide therapy of differentiated thyroid cancer: efficacy and toxicity.
    Czepczyński R; Matysiak-Grześ M; Gryczyńska M; Bączyk M; Wyszomirska A; Stajgis M; Ruchała M
    Arch Immunol Ther Exp (Warsz); 2015 Apr; 63(2):147-54. PubMed ID: 25403743
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Somatostatin receptor 2 expression determined by immunohistochemistry in cold thyroid nodules exceeds that of hot thyroid nodules, papillary thyroid carcinoma, and Graves' disease.
    Sancak S; Hardt A; Singer J; Klöppel G; Eren FT; Güllüoglu BM; Sen LS; Sever Z; Akalin NS; Eszlinger M; Paschke R
    Thyroid; 2010 May; 20(5):505-11. PubMed ID: 20450431
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Somatostatin receptors 2 and 5 are the major somatostatin receptors in insulinomas: an in vivo and in vitro study.
    Bertherat J; Tenenbaum F; Perlemoine K; Videau C; Alberini JL; Richard B; Dousset B; Bertagna X; Epelbaum J
    J Clin Endocrinol Metab; 2003 Nov; 88(11):5353-60. PubMed ID: 14602773
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of somatostatin receptor subtypes in human thyroid tumors: the immunohistochemical and molecular biology (RT-PCR) investigation.
    Pisarek H; Stepień T; Kubiak R; Borkowska E; Pawlikowski M
    Thyroid Res; 2009 Jan; 2(1):1. PubMed ID: 19173713
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of somatostatin and somatostatin receptor subtypes 1-5 in human normal and diseased kidney.
    Bhandari S; Watson N; Long E; Sharpe S; Zhong W; Xu SZ; Atkin SL
    J Histochem Cytochem; 2008 Aug; 56(8):733-43. PubMed ID: 18443363
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Loss of sst2 somatostatin receptor gene expression in human pancreatic and colorectal cancer.
    Buscail L; Saint-Laurent N; Chastre E; Vaillant JC; Gespach C; Capella G; Kalthoff H; Lluis F; Vaysse N; Susini C
    Cancer Res; 1996 Apr; 56(8):1823-7. PubMed ID: 8620499
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New pansomatostatin ligands and their chelated versions: affinity profile, agonist activity, internalization, and tumor targeting.
    Ginj M; Zhang H; Eisenwiener KP; Wild D; Schulz S; Rink H; Cescato R; Reubi JC; Maecke HR
    Clin Cancer Res; 2008 Apr; 14(7):2019-27. PubMed ID: 18381940
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential expression of somatostatin receptor subtype 1-5 proteins in numerous human normal tissues.
    Unger N; Ueberberg B; Schulz S; Saeger W; Mann K; Petersenn S
    Exp Clin Endocrinol Diabetes; 2012 Sep; 120(8):482-9. PubMed ID: 22976314
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Somatostatin receptor profiling in hepatic metastases from small intestinal and pancreatic neuroendocrine neoplasms: immunohistochemical approach with potential clinical utility.
    Nasir A; Stridsberg M; Strosberg J; Su PH; Livingston S; Malik HA; Kelley ST; Centeno BA; Coppola D; Malafa ME; Yeatman TJ; Kvols LK
    Cancer Control; 2006 Jan; 13(1):52-60. PubMed ID: 16508627
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incidentally Detected Thyroid Follicular Neoplasm on Somatostatin Receptor Imaging and Post-therapy Scan.
    Sood A; Singh H; Sood A; Basher RK; Mittal BR
    Indian J Nucl Med; 2017; 32(3):224-226. PubMed ID: 28680210
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of expression of somatostatin receptor 1, 2, 3, 5 and dopamine D2 receptor in spindle cell oncocytomas of posterior pituitary.
    Soukup J; Kasparova P; Kohout A; Rychly B; Skarkova V; Syrucek M; Gabalec F
    Pituitary; 2019 Feb; 22(1):70-78. PubMed ID: 30607746
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thyroid paraganglioma. Report of 3 cases and description of an immunohistochemical profile useful in the differential diagnosis with medullary thyroid carcinoma, based on complementary DNA array results.
    Castelblanco E; Gallel P; Ros S; Gatius S; Valls J; De-Cubas AA; Maliszewska A; Yebra-Pimentel MT; Menarguez J; Gamallo C; Opocher G; Robledo M; Matias-Guiu X
    Hum Pathol; 2012 Jul; 43(7):1103-12. PubMed ID: 22209341
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunocytochemical detection of somatostatin receptors sst1, sst2A, sst2B, and sst3 in paraffin-embedded breast cancer tissue using subtype-specific antibodies.
    Schulz S; Schulz S; Schmitt J; Wiborny D; Schmidt H; Olbricht S; Weise W; Roessner A; Gramsch C; Höllt V
    Clin Cancer Res; 1998 Sep; 4(9):2047-52. PubMed ID: 9748118
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Selective activation of somatostatin receptor subtypes differentially modulates secretion and viability in human medullary thyroid carcinoma primary cultures: potential clinical perspectives.
    Zatelli MC; Piccin D; Tagliati F; Bottoni A; Luchin A; Vignali C; Margutti A; Bondanelli M; Pansini GC; Pelizzo MR; Culler MD; Degli Uberti EC
    J Clin Endocrinol Metab; 2006 Jun; 91(6):2218-24. PubMed ID: 16569735
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Somatostatin receptor status in non-medullary thyroid carcinoma].
    Görges R; Kahaly G; Müller-Brand J; Mäcke H; Walgenbach S; Bruns C; Andreas J; Brandt-Mainz K; Bockisch A
    Nuklearmedizin; 1999; 38(1):15-23. PubMed ID: 9987777
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Initial Experience With Gallium-68 DOTA-Octreotate PET/CT and Peptide Receptor Radionuclide Therapy for Pediatric Patients With Refractory Metastatic Neuroblastoma.
    Kong G; Hofman MS; Murray WK; Wilson S; Wood P; Downie P; Super L; Hogg A; Eu P; Hicks RJ
    J Pediatr Hematol Oncol; 2016 Mar; 38(2):87-96. PubMed ID: 26296147
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Two peptide receptor ligands (99m)Tc-EDDA/HYNIC-Tyr(3)-octreotide and (99m)Tc-EDDA/HYNIC-(D)Glu-octagastrin for scintigraphy of medullary thyroid carcinoma.
    Kosowicz J; Mikołajczak R; Czepczyński R; Ziemnicka K; Gryczyńska M; Sowiński J
    Cancer Biother Radiopharm; 2007 Oct; 22(5):613-28. PubMed ID: 17979564
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The therapeutic value of SST-A octreotide alone or with adjuvant treatment in patients with advanced medullary thyroid carcinoma and positive (111)In-octreotide scan.
    Vainas I; Drimonitis A; Boudina M; Kaprara A; Iakovou I; Salem N; Koussis C
    Hell J Nucl Med; 2005; 8(1):43-7. PubMed ID: 15886753
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.